December 1, 2016Open Access

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

Key Points

Key points are not available for this paper at this time.

Abstract

Extended follow-up of the PLCO trial over a median of 15 years continues to indicate no reduction in prostate cancer mortality for the intervention arm versus the control arm. Because of the high rate of control-arm PSA testing, this finding can be viewed as showing no benefit of organized screening versus opportunistic screening. Cancer 2017;123:592-599. © 2016 American Cancer Society.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Pinsky et al. (Thu,) studied this question.

synapsesocial.com/papers/69e074f946ce12fc615574e5 https://doi.org/https://doi.org/10.1002/cncr.30474

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Reevaluating PSA Testing Rates in the PLCO Trial2016 · 196 citations
2More on Reevaluating PSA Testing Rates in the PLCO Trial2016 · 12 citations
3Prostate-Cancer Mortality at 11 Years of Follow-up2012 · 1,241 citations
4Changes in and Impact of the Death Review Process in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial2015 · 24 citations
5Regression Models and Life-Tables1992 · 26,660 citations

Bookmark

View Full Paper